# A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Treated Patients With Chronic Hepatitis B

> **NCT07190742** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Grand Theravac Life Sciences (Nanjing) Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Chronic Hepatitis B Virus

## Interventions

- **DRUG:** TVAX-008
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07190742
- **Lead sponsor:** Grand Theravac Life Sciences (Nanjing) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-01
- **Primary completion:** 2024-10-17
- **Final completion:** 2026-05-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07190742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07190742, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Treated Patients With Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07190742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*